Clinical Trials Browser

Phase 2 × Lymphoma × pembrolizumab × Clear all

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03990961 2026-02-20

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Terminated

5 enrolled 11 charts

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Phase 2 Suspended

18 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Phase 2 Active not recruiting

47 enrolled

Lymphoid

Lymphoma, Recurrence

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Phase 2 Active not recruiting

51 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03255018 2023-11-28

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Phase 2 Completed

12 enrolled 21 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

SPiReL

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Pembrolizumab in Neoplasms or Lymphomas

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.